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Zusammenfassung 
Das Harnblasenkarzinom ist der häufigste maligne Tumor der ableitenden Harnwege. Ca. 
70% der Patienten kommen initial mit einem nicht-muskel-invasiven Blasenkarzinom 
(NMIBC) zu Untersuchung. Nach den Leitlinien der European Association of Urology (EAU), 
werden NMIBC in 3 Risikogruppen eingeteilt: Niedriges, intermediäres und hohes Risiko. 
Dies ist die Grundlage für eine risikoadaptierte Therapie.  
Trotz umfrangreicher molekularbiologischer Forschungen in den vergangenen Jahren gibt es 
bisher keine geeigneten molekularen Marker für den klinischen Einsatz. Deshalb sind 
klinische und pathologische Faktoren wichtig, um das Risiko für Tumorrezidiv und 
-Progression zu bewerten. Auf der Basis einer Metaanalyse haben die EORTC- und die 
CUETO-Gruppe jeweils einen Risikoscore für NMIBC entwickelt. In der vorliegenden Studie 
werden potentielle prognostische Faktoren anhand der Daten der Urologischen Klinik der Uni 
Jena analysiert. Darüber hinaus erfolgt eine Evaluation der EORTC und CUETO 
Risikotabellen an diesem Patientenkollektiv. 
Es wurde eine retrospektive Auswertung aller Patienten mit NMIBC, die sich zwischen Januar 
2003 und Dezember 2011 einer transurethralen Resektion unterzogen, vorgenommen.. Zur 
Datenanalyse wurden die klinischen Befunde, die histopathologischen Ergebnisse des 
Operationspräparates und die Befunde der Nachsorgeuntersuchungen herangezogen: 
Geschlecht, Alter, bisherige Rezidivrate, Anzahl der Tumoren, Tumorgröße, 
Tumorlokalisation, pT-Stadium, Differenzierungsgrad, Vorliegen eines CIS, erste 
Nachresektion, pathologisches Ergebnis der Nachresektion, intravesikale BCG- oder 
Chemotherapie, Rezidiv und Progression. Die Patienten wurden drei Risikogruppen nach der 
EAU Klassifikation eingeteilt.. 
Non den in die Studie eingeschlossenen 611 Patienten hatten 197 (32%) ein nidriges, 251 
(41%) ein intermediäres und 163 (27%) ein hohes Risiko. Bei 535 (87.6%) Patienten wurde 
eine Nachresektion durchgeführt. Nachbeobachtungsdaten konnten in 528 Fällen erhoben 
werden. Die mediane Nachbeobachtungszeit lag bei 60 Monaten (1-143Mo) nachbeobachtet 
Die Gesamtwahrscheinlichkeit für ein Tumorrezidiv zeigten lag nach einem Jahr nach 
Diagnose bei 18,6%, nach zwei Jahren bei 33.7% und nach fünf Jahren bei 43.9%. Die 
Progressionsrate lag bei 0.9%, 2.6%, und 6.6% nach ein, zwei und fünf Jahren. 
In der Subgruppe der pTaG1/G2 Tumoren führte die sekundäre TUR zu einem signifikant 
reduzierten Rezidivrisiko. Insgsamt ergibt die statistische Auswertung dass die vorherige 
Rezidivrate und das pathologische Ergebnis der Nachresektion unabhängige prognosische 
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Faktoren für ein Tumorrezidiv waren. Alter, vorherige Rezidivrate, pT-Stadium, 
Differenzierungsgrad, und pathologische Ergebnis der Nachresektion waren unabhängige 
prognosische Faktoren für eine Tumorprogreession. Im Vergleich zur tatsächlichen 
Rezidivrate in unserem Patientenkollektiv unterschätzten die CUETO-Risikotabellen das  
Rezidivrisko. Demgegenüber entsprach die Progressionrate den Vorhersagewerten der 
EORTC und CUETO Tabellen. 
Insgesamt zeigt die Studie eine hohe Bedeutung für die transurethrale Nachresektion beim 
NMIBC. Die verfügbaren Risikokalkulatoren der EORTC- bzw. CUETO-Gruppe eignen sich 
vor allem für die Vorhersage des Progressionsrisikos, weniger für die Vorhersage eines 
Tumorrezidivs. Vor allem bei Patienten mit hohem Risiko ist die Aussagekraft dieser 
Kalkulatoren in dem vorliegenden Kollektiv mit routinemäßiger Nachresektion allerdings 
eingeschränkt .  
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Summary 
Bladder cancer is the most common malignancy of the urinary tract. Approximately 70% are 
non-muscle-invasive tumors at initial diagnosis. Based on the recommendation of EAU 
guidelines, non-muscle-invasive bladder cancer (NMIBC) is stratified into three categories, 
including low, intermediate, and high risk groups of recurrence and progression. This allows 
urologists for better treatment selection.  
Molecular research has provided great insight into the biology of bladder cancer. However, no 
molecular marker has been accepted as a standard diagnostic procedure in clinical practice. 
Therefore, clinical and pathological variables still play important roles to predict disease 
recurrence and progression. The currently used risk categories are based on historical data 
from the EORTC and CUETO groups. However, these models, may not apply to NMIBC 
patients treated nowadays e.g. if patients undergo routine re-resection and BCG maintenance 
therapy. Thus, the goal of our study was to distinguish putative important predictive factors 
and to evaluate the utility of both existing models in our patients.  
A retrospective single center study was performed including treated patients with NMIBC  
between January 2003 and December 2011 at our department. The following clinical and 
pathologic data were analyzed: gender, age, prior recurrence rate, number of tumors, tumor 
size, location of tumors, tumor stage, tumor grade, presence of CIS, second TURB, second 
TUR pathology, intravesical treatment, recurrence and progression of bladder tumor. Patients 
were stratified into three risk categories according to the EAU guidelines. 
Of the 611 patients, 197 (32%), 251 (41%) and 163 (27%) were assigned to the low, 
intermediate, and high risk category, respectively. Of these patients 535 (87.6%) underwent a 
second TUR. Overall, 528 patients were included ultimately in our follow-up study. The 
median follow-up was 60 months (range: 1-143 months). The overall recurrence rates in our 
cohort was 18.6%, 33.7%, and 43.9% after the 1st, 2nd and 5th year, respectively. The 
corresponding progression rates were 0.9%, 2.6%, and 6.6%.  
A second TUR was associated with a reduced risk of disease recurrence in primary TaG1/G2 
patients. Overall, prior recurrence rate and second TUR pathology are independent predictors 
of disease recurrence, whereas age, prior recurrence rate, tumor stage, tumor grade, second 
TUR, and second TUR pathology are prognostic factors for disease progression. The CUETO 
recurrence risk table severely underestimates the risk of disease recurrence in our cohort. 
However, the EORTC and CUETO risk tables are suitable tools to estimate disease 
progression in our cohort. 
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In summary, second TUR is of paramount importance and should be applied to all NMIBC 
patients. The EORTC and CUETO risk models are suitable to estimate progression risk. 
However, both risk calculators do not accurately predict risk of  recurrence ,especially in the 
high risk patients. The latter may be due to the routine use of second TUR in our cohort. 
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1  Introduction 
1.1 Epidemiology and Etiology 
Bladder cancer (BC) is the 11th most commonly diagnosed cancer and the 14th leading cause 
of cancer deaths worldwide, with an estimated 382,700 new cases and 150,300 deaths in 2010 
(Ferlay et al. 2010).The world global age standardized mortality rate is 3 per 100,000 for men 
versus 1 per 100,000 for women. In the European Union, age standardized mortality rate is 8 
for men and 3 per 100,000 for women, respectively. At initial diagnosis, approximately 70% 
of the patients have non-muscle-invasive bladder cancer (NMIBC). Of those patients, 70% are 
confined to the bladder mucosa (Ta), 25% in the lamina propria (T1) and 5% have carcinoma 
in situ only (CIS) (Herr et al. 2001).  
In Germany, more than 13,000 were diagnosed with non-invasive papillary carcinoma or CIS 
tumors of the bladder. The majority of BC cases are transitional cell carcinomas. One in 23 
men and one in 62 women are identified with BC during their lifetime. The median diagnostic 
age at diagnosis is 72 years among men and 74 years among women. In the state of Thuringia, 
incidence and mortality of BC are higher in men and lower in women compared with the 
average of Germany (Robert Koch-Institute, 2014). 
The etiology of BC appears to be multifactorial with exogenous environmental factors, as 
well as endogenous molecular factors. Firstly, tobacco smoking is the most important risk 
factor for BC, causing 50-65% of male cases and 20-30% of female cases (Burger et al. 2013, 
Freedman et al. 2011). However, an association between tobacco consumption and 
progression or death resulting from BC has never been found (Murta-Nascimento et al. 2007). 
Occupational exposure is the second most important risk factor for BC. The two groups of 
chemicals known to cause bladder cancer are aromatic amines and polycyclic aromatic 
hydrocarbons (Colombel et al. 2008). In 2013, the International Agency for Research on 
Cancer classified pioglitazone hydrochloride as probably carcinogenic to humans with regard 
to BC. Chronic inflammatory damage of the bladder mucosa also increases the risk of bladder 
carcinoma ( Burger et al. 2013). 
Furthermore, other factors e.g., external-beam radiotherapy and chronic urinary tract infection 
have been considered related to BC. The links remain, however, controversial. 
1.2 Economics 
BC is one of the most common malignant diseases worldwide and treatment costs are 
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substantial. In terms of clinical and economical aspects, it is important to remember that BC is 
often a chronic disease.  
Based on the statistic drawn from USA, BC costs from diagnosis-to-death between $89,287 
and $202,203 (Botteman et al. 2003). Another study in UK indicated that transurethral 
resection of the bladder (TURB) represents the largest BC expenditure, accounting for 71% of 
treatment costs (Sangar et al. 2005). 
NMIBC has an average 60–80% recurrence rate. 40–60% recurrences occur within 2 years, 
with 10-30% of the patients finally developing muscle-invasive bladder cancer (MIBC) which 
requires more invasive and costly treatment (Herr 2000). The costs of TURB and cystectomy 
in Germany are $2,967 and $20,507, respectively. Progression from NMIBC to MIBC 
obviously increases overall treatment costs.  
Based on tumor risk category, the European Association of Urology (EAU) guidelines 
recommend intravesical chemotherapy or adjuvant immunotherapy using BCG following 
TURB. Especially in high-risk BC monitoring generates significant on-going costs. About 
75% of the post-diagnosis costs relate to preoperative and intraoperative management 
including postoperative complications, tri-annual examinations and semi-annual diagnostic 
and laboratory testing (Marchetti et al. 2000). 
On the other hand, there is also the enormous financial burden that cancer exerts on patients 
and their families. Yabro and colleagues showed that the estimated patient’s cost for traveling, 
waiting for appointments and receiving services or procedures during the first 12 months after 
primary diagnosis was as much as $5605 in USA (YabroV et al. 2007). 
The high incidence and long term survival leads to a high prevalence of BC. Lifelong routine 
monitoring and treatment are often necessary. Therefore, the cost in bladder cancer is the 
highest of all cancers per patient. 
1.3 Staging 
The tumor, node and metastasis (TNM) classification of malignant tumors is the method most 
widely used to classify the extent of cancer spread. Recently, a seventh edition was published 
(Table 1), effective as of 2010. There are no significant modifications about BC in comparison 
with the previous 2002 edition. 
According to the TNM classification system, a papillary tumor confined to the mucosa is 
classified as stage Ta. Tumors that have invaded the lamina propria are classified as stage T1. 
Also CIS are flat, high-grade tumors that are confined to the mucosa. Stage Ta, CIS (mucosa) 
and stage T1 (submucosa) define the group of NMIBC. 
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Table 1  2009 TNM classification of urinary bladder cancer 
 
T   Primary tumor 
TX 
T0 
Ta 
Tis 
T1 
T2  
 
 
T3  
 
 
T4 
Primary tumor cannot be assessed 
No evidence of primary tumor 
Non-invasive papillary carcinoma 
Carcinoma in situ: ‘flat tumor’ 
Tumor invades subepithelial connective tissue 
Tumor invades muscle 
T2a  Tumor invades superficial muscle (inner half) 
T2b  Tumor invades deep muscle (outer half) 
Tumor invades perivesical tissue: 
T3a  Microscopically 
T3b  Macroscopically (extravesical mass) 
Tumor invades any of the following: prostate, uterus, vagina, pelvic wall, 
abdominal wall 
T4a  Tumor invades prostate, uterus or vagina 
T4b  Tumor invades pelvic wall or abdominal wall 
N   Lymph nodes 
NX 
N0 
N1  
N2  
N3 
Regional lymph nodes cannot be assessed 
No regional lymph node metastasis 
Metastasis in a single lymph node in the true pelvis  
Metastasis in multiple lymph nodes in the true pelvis 
Metastasis in common iliac lymph node(s) 
M   Distant metastasis 
MX 
M0 
M1 
Distant metastasis cannot be assessed 
No distant metastasis 
Distant metastasis 
 
 
1.4 Histological Grading   
In 1998, a new classification of non-invasive urothelial tumors was proposed by the World 
Health Organization (WHO) and the International Society of Urological Pathology (ISUP) 
(1998 WHO/ISUP classification) and published by the WHO in 2004 (Epstein et al.1998, 
Sauter et al. 2004).The WHO 2004 classification system is recommended for classification 
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and grading in urothelial neoplasms (Table 2).  
Compared with the old 1973 WHO system,, a new subgroup papillary urothelial neoplasm of 
low malignant potential (PUNLMP) is described, which is defined as a papillary fibrovascular 
growth covered with proliferated urothelium, exceeding the normal thickness, this 
corresponds largely to grade 1 papillary transitional cell carcinoma of the old 1973 WHO 
system, though not completely.  
Table 2 WHO grading of urothelial tumor in 1973 and 2004 
 
1973 WHO grading 
Urothelial papilloma 
Grade 1: well differentiated 
Grade 2: moderately differentiated 
Grade 3: poorly differentiated 
2004 WHO grading 
Papillary lesions 
Urothelial papilloma (completely benign lesion) 
Papillary urothelial neoplasm of low malignant potential 
Low-grade papillary urothelial carcinoma 
High-grade papillary urothelial carcinoma 
Flat lesions 
Hyperplasia (flat lesion without atypia or papillary aspects) 
Reactive atypia (flat lesion with atypia) 
Atypia of unknown significance 
Urothelial dysplasia 
Urothelial CIS 
 
Urothelial carcinoma in situ (CIS) was firstly reported as a distinct phenomenon by Melicow 
(Melicow 1952). Despite the non-invasive character of CIS, it was suspected to possess 
aggressive tumor biology and tendencies towards early progression (Witjes 2004). CIS is 
malignant neoplasia of the urothelium, which is flat and not protruding into the bladder and 
which does not invade the lamina propria. While low grade non-invasive lesions are thought 
to derive from chromosome 9 abnormalities and mutations in the fibroblast growth factor 
receptor gene, CIS is marked by deletions of 19p13 resulting in TP53 mutations with 
consecutive prevention of cell cycle arrest and generalized genetic instability (Hartmann et al. 
2002). 
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In terms of tumor distribution, the grading categories of the 2004 WHO system do not directly 
translate from the 1973 WHO system categories (May et al.2010, Schned et al. 2007). Most 
clinical trials published so far on bladder cancer have been performed using the 1973 WHO 
classification. Therefore, until the 2004 WHO classification has been validated by further 
clinical trials, BC should be graded using both the 1973 and the 2004 WHO classifications.  
1.5 Diagnosis 
1.5.1 Hematuria 
In general, the painless hematuria is a cardinal presenting symptom of NMIBC. However, 
hematuria may be accompanied by irritative voiding symptoms in patients with CIS. The 
incidence of BC is 17-18.9% in those macroscopic hematuria and 4.8-6% in patients 
presenting with microscopic hematuria (Edwards et al. 2006, Datta et al. 2002, Mishriki et al. 
2008). It is unknown if early detection of BC associated with asymptomatic microscopic 
hematuria leads to an improved outcome (Kamat et al. 2013). 
1.5.2 Urinary Cytology and Markers 
Urine cytology is the morphologic features of urothelial cells, which can be used to screen 
and evaluate patients at high-risk urothelial tumors and to monitor recurrence, progression, or 
response to treatment in patients with a known history of NMIBC. Sensitivity and positive 
predictive value are particularly high in high-grade urothelial tumors as well as in cases of 
CIS in which sensitivities can exceed 90%. Cytology is less effective for low-grade urothelial 
tumors and as a qualitative technique is subject to considerable variation in interpretation 
(Gaston and Pruthi 2004). 
The specificity of cytology is superior to that of most of the available bladder tumor markers. 
Currently, combinations of cytology and urinary biomarkers have also been reported. In a 
study conducted by Horstmann, 221 patients undergoing cystoscopic surveillance for NMIBC 
were evaluated with urine cytology, NMP22 testing, fluorescence in situ hybridization (FISH 
Test) , and ImmunoCyt. Sensitivity increased to over 90% and negative predictive value 
increased to over 80% with combinations of 2 or 3 biomarkers, although specificity was 
reduced to an average of 44% with 2 biomarkers and 35% with 3 biomarkers (Horstmann et al. 
2009). However, none of the markers has achieved acceptance as a standard diagnostic 
procedure in clinical practice (Babjuk et al.2011). Those investigated tests and identified 
markers include the BTA TRAK test, NMP22 BladderChek assay, ImmunoCyt test, FISH test, 
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BLCA-4, hyaluronic acid, telomerase, microsatellite polymorphism analyses, cytokeratins, 
and survivin (Konety 2006). 
1.5.3 Cystoscopy 
The combination of urine cytology and cystoscopy has been considered as the gold standard 
for the diagnosis and surveillance of BC. White light endoscopic examination of both the 
urethra and the bladder remains the gold standard for the diagnosis for multiple diseases of 
the lower urinary tract, including urothelial carcinoma. The diagnosis of papillary BC 
ultimately depends on cystoscopic examination of the bladder and histological evaluation of 
the resection specimen. A careful description of the urothelial lesions is necessary, including 
the site, size, number, and appearance of the tumors, as well as a description of mucosal 
abnormalities.  
Photodynamic diagnosis (PDD) is currently recommended for treatment of patients with 
newly diagnosed lesions suspicious for NMIBC, examination of patients with positive urine 
cytology but negative findings on white light cystoscopy (WLC), and treatment of multifocal 
recurrent BC. PDD can improve detection of disease, especially CIS. Improved visualization 
leads to reduced rates of residual tumor at first-look cystoscopy and perhaps reduced rates of 
recurrence (Filbeck et al. 2002). The advantage of WLC plus PDD over WLC alone in the 
visualization and staging of BC is widely accepted. However, there may be artificial 
fluorescence during PDD examination. Folds of the urothelium will cause such artifact, and 
therefore the bladder should be sufficiently dilated. Other common sites are along blood 
vessels, on the trigone, and around the ureteric orifices. Grossman demonstrated a slightly 
higher false-positive rate due to nonspecific inflammation that can occur after treatment of a 
urinary tract infection, after TURB, or after intravesical therapy with Bacillus 
Calmette-Guérin (BCG) (Grossman et al. 2007).  
1.5.4 Imaging 
If hematuria is the initial symptom, imaging will be performed to evaluate the upper urinary 
tract especially with regard to the putative presence of upper tract tumors. These occur in less 
than 5% of patients with a known history of lower tract cancer (Messing EM and Catalona W. 
1998). Options for imaging are ultrasonography, intravenous urography, computed 
tomography (CT), magnetic resonance imaging, or a combination of these examinations. 
Ultrasonography is primarily used to evaluate the renal parenchyma.  
Improvements in the technical quality of ultrasonography have also resulted in improved 
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performance of this imaging modality in detecting BC. The reported sensitivities are 63-98% 
and specificity is 99% with respect to BC (Datta et al. 2002). CT urography permits 
evaluation of both the renal parenchyma and other pathologic conditions within the 
genitourinary tract. A meta-analyses of 5 studies of CT urography indicated a pooled 
sensitivity of 96% and a pooled specificity of 99% in identifying upper urinary tract 
malignancy (Chlapoutakis et al. 2010). In imaging of the bladder, ultrasonography and CT 
urography have similar specificities in the diagnosis of BC. However, CT urography has 
higher sensitivity (89.7% vs 69%) (Knox et al. 2008). Furthermore, CT urography 
demonstrates the size of lesions within the bladder, extravesical spread, and pelvic lymph 
node status whereas ultrasonography may not. On the other hand, the disadvantages of CT 
urography are relatively high radiation doses, need for intravenous contrast medium, limited 
availability, and relatively high cost. 
1.5.5 Diagnostic Transurethral Resection of Bladder Tumors 
Ultimately, the diagnosis of urothelial carcinoma is made upon excision of the vesical lesion 
by TURB (Shelfo et al. 1997). The diagnostic purpose of TURB is to obtain a specimen 
sufficient to permit proper estimation of the tumor, which is based largely on stage, grade, 
histological subtype and the presence of lymphovascular invasion. 
The bladder should be examined perfectly with both a 30-degree and a 70-degree lens. 
Visualization of the anterior bladder neck may be improved by using a 120-degree scope or by 
using retroflexion with a flexible cystoscopy. The dome and anterior bladder are examined by 
applying gentle suprapubic pressure to move the bladder mucosa down and closer to the lens. 
It is critical to maintain optimal bladder distention during cystoscopy and TURB. Finally, 
prostatic urethral biopsy may be performed in selected cases using electrocautery loop 
resection including the 5 o’clock and 7 o’clock positions of the verumontanum. 
1.6 Treatment Strategy   
The major goals in treating patients with NMIBC are to reduce recurrence frequency and to 
prevent progression to muscle-invasive disease. The optimal management of NMIBC is based 
on three criteria: complete first TUR, effective intravesical treatment and optimal time 
intervention with radical cystectomy in high-risk patients (Kulkarni et al. 2010).  
In most cases of NMIBC, tumors are treated initially with TURB. A precise documentation of 
the cystoscopic examination is necessary. Generally, the site of tumor(s), tumor configuration, 
(papillary or sessile), estimates of the number of tumors and their sizes should be noted to 
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assist evaluation during second TUR and follow-up. After resection of all visible tumors, 
adjuvant intravesical immunotherapy or chemotherapy can be used (Messing EM and 
Catalona W. 1998). Urologists must always weight the risks and benefits of aggressive versus 
conservative treatment of NMIBC. 
1.6.1 TURB and Second Resection 
TURB is the first-line treatment for patients with NMIBC. The goal of TURB is to make the 
correct diagnosis and remove all visible lesions. It is a crucial procedure in the diagnosis and 
treatment of BC. A careful cystoscopic evaluation and eradication of tumor is an important 
therapeutic intervention at primary diagnosis. 
TURB not only establishes staging of the tumor, but it also serves as the basis for adjuvant 
treatment decisions and follow-up intervals. The strategy of resection depends on the size of 
the lesion. Small tumors (< 1 cm) can be resected en bloc, which includes the entire tumor 
and part of the underlying bladder wall. Larger tumors (＞1 cm) should be resected separately 
in fractions, including the exophytic part of the tumor, the underlying bladder wall associated 
with the detrusor muscle, and the edges of the resection area. This approach provides enough 
information about the vertical and horizontal extent of the tumor and helps to improve 
resection completeness (Richterstetter et al. 2012).  
The significant risk of residual tumor after initial TURB of Ta, T1 lesions has been 
demonstrated (Miladi et al. 2003). Therefore, a second TUR (second TUR) is recommended 
in the following situations (Babjuk et al. 2011): 
• After incomplete initial TUR; 
• If there was no muscle in the specimen after initial resection, with exception of Ta G1 
tumors and primary CIS; 
• In all T1 tumors; 
• In all G3 tumors, except primary CIS. 
In summary, a second TUR has to be performed in the case of high-grade malignancy or 
incomplete resection according to the EAU guidelines. 
1.6.2 Intravesical Chemotherapy 
In view of the relatively high rates of recurrence, adjuvant intravesical therapy can be 
considered. The goals of intravesical treatment are to: reduce the implantation of tumor cells 
after TURBT, eradicate any residual tumors, reduce tumor recurrence and prevent tumor 
progression. 
1 Introduction 
13 
The EAU guidelines recommend one immediate postoperative dose of intravesical 
chemotherapy at the initial resection of suspected BC with low-risk NMIBC. However, those 
of intermediate risk require additional intravesical chemo- or immunotherapy. Oosterlinck and 
associates found one single instillation with a chemotherapeutic agent within 24 h can 
decrease the recurrence rate by almost 50% (Oosterlinck et al. 1993). For other patients with 
multiple tumors, a single immediate instillation is considered as an incomplete treatment 
because of the potential likelihood of recurrence and/or progression. In order to reduce the 
number of recurrences, a series of intravesical instillations is given postoperatively. The 
recurrence rate of NMIBC after intravesical chemotherapy decreases in the short term, but 
this benefit disappears in the long term (van der Heijden et al. 2009).  
It is still controversial how long and how frequently chemotherapy instillations should be 
given. Therefore, the optimal regimen, frequency and duration of intravesical chemotherapy 
are not yet consent, although the EAU recommendation is treatment for no more than 1 year 
(Babjuk et al. 2011). Generally, Mitomycin C, Doxorubicin, Epirubicin, and Gemcitabine are 
used in clinical practice. 
1.6.3 Intravesical Bacillus Calmette-Guérin Immunotherapy 
Bacillus Calmette-Guérin, first indicated as a tuberculosis vaccine, has had widespread use in 
intravesical immunotherapy since the 1970s (Morales et al. 1976). Intravesical BCG is 
considered the most effective intravesical therapy for high-risk NMIBC and thus the 
recommended adjuvant non-surgical treatment (Herr 2008). 
Initiation of intravesical BCG therapy is usually delayed for two to three weeks following 
TURB to allow for healing of the urothelium thereby reducing the risk of systemic side effects. 
Most patients develop an inflammatory immunologic response to BCG during a typical 
induction course of six weekly instillations. It has been suggested that BCG reduces the risk 
of progression of intermediate- and high-risk tumors if it is applied including a maintenance 
schedule. Optimal dosing and instillation schedules have not yet been established but some 
trials have demonstrated that a reduced dosing regimen (one-third dose) may be as effective 
as the standard dose but has fewer side effects (Martinez-Pineiro et al. 2005). 
Unfortunately, BCG instillation is associated with a considerable number of local and 
systemic side effects. Of the 1316 intermediate- and high-risk patients treated with BCG,   
Brausi et al reported 30.6% with systemic side effects, whereas 69.5% with local or systemic 
side effects (Brausi et al. 2014). Therefore, the use of BCG is usually restricted to patients 
with intermediate and high risk of recurrence and progression. 
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1.6.4 Radical Cystectomy  
High-risk NMIBC must be handled with the most effective treatment to prevent progression 
to muscle-invasive disease. However, if progression occurs or if patients are at high risk for 
progression radical cystectomy is the choice of treatment. 
The only proven method to prevent progressive disease is to do an early cystectomy (Skinner 
2007). Moreover, early cystectomy has three advantages. The first is good pathological 
staging through precise assessment with adequate lymph node status. The second is an early 
stage of the disease, which makes a nerve-sparing cystectomy possible. The third is a great 
reduction in the risk of subsequent recurrences and mortality. 
Potential benefit must be outweighed against the risks, morbidity, and impact on quality of 
life of radical cystectomy. It is crucial to propose immediate radical cystectomy to those 
patients with non-muscle-invasive tumor who are at highest risk of progression. It is also 
recommended in BCG failures (e.g. persistence of high-risk disease at 6 months) and an 
option in patients with a higher risk for progression based on adverse prognostic factors.  
Open radical cystectomy is the gold-standard treatment for MIBC and for high-risk recurrent 
NMIBC. Recently, laparoscopic radical cystectomy and robot-assisted radical cystectomy 
have been explored. The advantages include decreased blood loss, reduced postoperative pain, 
early healing of bowel function and shorter hospital stay. 
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2  Aims of the Study 
The appropriate assignment of risk is the first principle in the management of NMIBC. The 
decision about when to treat, how to treat, and the optimal combination of treatment 
modalities is ultimately based on an understanding of the risk of disease recurrence and 
progression. Because NMIBC is considered a heterogeneous disease, an accurate prognostic 
estimate for each individual patient is important. In terms of defining a set of routinely 
assessed clinical and pathological factors, the European Organization for Research and 
Treatment of Cancer (EORTC) and the Spanish Urological Club for Oncological Treatment 
(CUETO), respectively, proposed a scoring system and risk tables to calculate the probability 
of recurrence and progression in individual patients with NMIBC. However, these 
nomograms were derived from historical clinical trials and may not apply to patients treated 
nowadays (e.g. using routine second TUR and maintenance BCG-schedules). Therefore, the 
following aims of this study were defined: 
z Retrospective analyses of clinical and pathological results in patients suffering from 
NMIBC at the Jena University Hospital. 
z Determine the utility of EAU risk stratification in patients with NMIBC 
z Evaluation of second-look transurethral resection in patients with NMIBC. 
z Estimate the value of second TUR pathology on disease recurrence and progression  
z Investigation of independent prognostic factors on risks of recurrence and progression in 
patients with NMIBC 
z Provide long term follow-up of primary TaG1/G2 NMIBC in our cohort 
z External validation of EORTC and CUETO scoring models to predict recurrence and 
progression in patients with NMIBC in our institution 
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3  Patients and Methods 
3.1 Study Design  
A single retrospective study of NMIBC was conducted by the department of urology, Jena 
University Hospital, Germany. We retrospectively analyzed the patients with a  
histology-proven diagnosis of NMIBC between January 2003 and December 2011. The 
medical records were collected through the SAP system of the Jena University Hospital, the 
oncological center of the Jena University and family doctors of the patients, respectively. The 
following clinical and pathologic data were analyzed: gender, age, prior recurrence rate, 
number of tumors, tumor size, location of tumors, tumor stage, tumor grade, presence of CIS, 
second TURB, second TUR pathology, intravesical treatment, recurrence and progression of 
bladder tumors. The data associated with disease recurrence and progression after the initial 
TURB were documented from medical records until April 2015. All patients had 
histologically confirmed NMIBC and were treated according to the EAU guidelines and 
current standard. 
The total information were recorded in a database ( Access; Microsoft®). Thus, a Microsoft® 
Excel table was subsequently generated that included the clinicopathologic factors and 
follow-up information. Patients with concomitant upper urinary tract tumor, ureteral tumor, or 
other cancers at first TUR were excluded from the study. In addition, all patients with primary 
CIS or at least T1G3 in diagnostic TURB, who underwent subsequently radical cystectomy 
within 6 months after initial TURB , were also excluded in follow-up analyses. Remaining 
NMIBC, including Ta, T1 and concurrent CIS, were included in the present study. All data 
were anonymized before being used . 
3.2 Study Population 
Between 01.01.2003 and 31.12.2011, a total of 611 patients of NMIBC underwent TURBT at 
the department of urology, Jena University Hospital. 
In the analyses of follow-up, 83 patients who were lost at follow-up were excluded . 
Ultimately, 528 patients were available for investigation of follow-up. The study was 
performed in accordance with the principles of the Declaration of Helsinki, and was approved 
by the institutional review board of the Jena University Hospital. 
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3.3 Pathological Data 
Pathological assessment of specimens obtained by TURB is an essential step in making 
decision of the diagnosis and treatment for bladder cancer. Tumor stage and grade of TURB 
specimens were diagnosed by pathologists in our university hospital, according to the 2002 
TNM classification and the 1973 World Health Organization system, respectively (Greene et 
al. 1973). 
Pathologists must report accurately and with minimal variability the key pathologic 
parameters using terminologies that are well understood by clinicians. Generally, The 
pathological data should include (Lopez-Beltran et al. 2004): 
• Location of the evaluated sample  
• Grade of each lesion; 
• Depth of tumor invasion (stage); 
• Presence of CIS; 
• Presence of detrusor muscle in the specimen; 
• Presence of lymphovascular invasion; 
• Presence of aberrant histology. 
Meanwhile, adequate clinical information is also important to pathologists in judging the best 
approach in handling and processing the surgical specimens. 
3.4 EAU Risk Stratification in TaT1 Bladder Cancer 
The risk definitions proposed by the EAU, AUA, ICUD, NCCN and IBCG vary and in some 
instances are cumbersome for use in routine clinical practice. In our institution, risk 
stratification recommended by the EAU Guidelines Panel will facilitate treatment modalities, 
including low, intermediate and high risk category, in patients suffering from NMIBC (Table 
3). 
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Table 3  Risk stratification recommended by EAU guidelines 
Risk category Definition 
Low-risk tumors Primary, solitary, Ta, G1, < 3 cm, no CIS 
Intermediate-risk tumors All cases between categories of low and high risk 
High-risk tumors 
Any of the following: 
• T1 tumors 
• G3 tumors 
• CIS 
• Multiple and recurrent and large (> 3 cm) Ta G1G2 
tumors (all these conditions must be presented) 
3.5 Treatment Regimen 
The EAU recommend the high-risk patients to undergo second TUR in 2-6 weeks after initial 
resection, however, in our clinical practice, the majority of low-risk and intermediate-risk 
patients were also treated with a second TUR. For intravesical therapy, the types of adjuvant 
intravesical chemotherapies were divided into three groups:1)The low-risk group was 
recommended with single immediate postoperative instillation of doxorubicin or 
mitomycin-C; 2) The intermediate-risk group was recommended with one immediate 
instillation of chemotherapy followed by further instillations, either chemotherapy for a 
maximum of 1 year or 1 year full-dose BCG, which depended on each surgeon’s decision; 3) 
The high-risk group was recommended with intravesical full-dose BCG instillations, 
including 6 to 8 weekly instillation and maintenance for 1-3 years, or cystectomy. All 
therapies are adapted according to personal and subjective conditions. For the elderly patients 
(more than 80 years), less aggressive treatments are usually performed, e.g. palliative TUR. 
3.6 Recurrence and Progression   
About 50-70% patients with NMIBC develop recurrence within 5 years, and 25% eventually 
develop muscle-invasive disease. Lifelong surveillance is therefore mandatory in the 
management of NMIBC (Fritsche et al. 2010). Clinical prognostic factors for tumor 
recurrence and progression are multiplicity, tumor stage, tumor grade, and tumor size.  
Recurrence was defined as a new histology-proven tumor appearing in the bladder after initial 
TURB. Disease progression is recognized as one of the most relevant clinical outcomes in 
patients with NMIBC (Ta/T1/CIS). The commonly used definition of progression is from Ta, 
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T1 or CIS to stage T2 or higher disease in the bladder. Both recurrence and progression were 
diagnosed by cystoscopy and/or cytology and were further confirmed by histological 
examination after TUR. 
The following were the endpoints of this study: 
Time to first recurrence (Recurrence-free interval): time from cancer diagnosis to the date of 
the first bladder recurrence. Patients who were still alive and without recurrence were 
censored at the date of the last available follow-up cystoscopy.  
Time to progression to muscle invasive disease (Progression-free survival): time from cancer 
diagnosis to the date of first increase to stage T2 or higher disease on pathological 
examination in the bladder. Patients who were still alive and without muscle invasion were 
censored at the date of the last available follow-up cystoscopy. 
Currently, the IBCG proposes the definition of NMIBC progression as an increase in T stage 
from CIS or Ta to T1 (lamina propria invasion), development of T2 or greater or lymph node 
(N+) disease or distant metastasis (M1), or an increase in grade from low to high (Lamm et al. 
2014). 
Patients known to have died from causes unrelated to bladder cancer were censored in the 
recurrence and progression analyses. Patients who underwent radical cystectomy in the 
staging of NMIBC and were not upstaged to muscle invasive disease were censored because 
they were no longer at risk of local progression. 
3.7 Follow Up 
The follow-up of NMIBC patients was calculated from the first TURB to the last cystoscopy 
procedure or the last TURB in the medical records. According to the EAU guidelines and our 
usual procedure , a subsequent cystoscopy was advised every 3 months for a period of 2 years  
subsequently every 6 months in the third, forth and fifth year and yearly thereafter. Patients 
with intermediate and high risks of progression should undergo cystoscopy and 
supplementary urinary cytology. The follow-up of the upper urinary tract (CT or intravenous 
urography) is recommended yearly in NMIBC patients at high risk of progression (Babjuk et 
al. 2011). The potential risk for disease recurrence and progression even in the long term 
typically requires lifelong follow-up (Leblanc et al.1999, Messing EM and Catalona W. 
1998) . 
Clinical follow-up involves an appropriate patient history including voiding symptoms and 
hematuria, urinalysis, cystoscopy, and urine cytology. Although many urine-based tumor 
markers have been developed, their role in surveillance has not been sufficiently validated, 
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and their use is not recommended in the current guidelines˄van Rhijn et al. 2005˅. 
3.8 EORTC and CUETO Models 
In order to estimate risk of recurrence and progression, the European Organization for 
Research and Treatment of Cancer (EORTC) proposed a scoring system and risk tables (Table 
4 and Table 5)(Sylvester et al.2006) .For individual prediction of the risk of disease recurrence 
and progression at different intervals after TURB, application of EORTC risk tables and 
calculator (http://www.eortc.be/tools/bladdercalculator/) is strongly recommended. 
 
Table 4 Weights used to calculate recurrence and progression scores ( EORTC) 
 
Factor Recurrence score Progression score 
No. of tumors  
Single 0 0 
2-7 3 3 
≥8 6 3 
Tumor diameter  
＜3cm 0 0 
≥3cm 3 3 
Prior recurrence rate  
Primary 0 0 
≤1 recurrence per year 2 2 
≥1 recurrence per year 4 2 
Category  
Ta 0 0 
T1 1 4 
Concomitant CIS  
No 0 0 
Yes 1 6 
Grade(1973 WHO)  
G1 0 0 
G2 1 0 
G3 2 5 
Total score 0-17 0-23 
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Table 5 Recurrence and progression probabilities at 1 and 5 years ( EORTC) 
 Probabilities at 1 y 
 (95% CI) 
Probabilities at 5 y 
 (95% CI) 
Recurrence score  
0 15(10-19) 31(24-37) 
1-4 24(21-26) 46(42-49) 
5-9 38(35-41) 62(58-65) 
10-17 61(55-67) 78(73-84) 
Progression score  
0 0.2(0-0.7) 0.8(0-1.7) 
2-6 1(0.4-1.6) 6(5-8) 
7-13 5(4-7) 17(14-20) 
14-23 17(10-24) 45(35-55) 
 
The main limitation of the EORTC risk tables is that small patients were treated with BCG 
therapy. To overcome this limitation, the Spanish Urological Club for Oncological Treatment 
(CUETO) developed a modified model using gender, age, prior recurrence rate, number of 
tumors, cancer stage, CIS, and WHO grade, which predicts the short- and long-term 
probability of disease recurrence and progression at the basis of data from 1,062 patients 
treated by BCG instillation (Table 6 and Table 7) (Fernandez- Gomez et al. 2009). 
Table 6 Recurrence and progression probabilities at 1, 2 and 5 years ( CUETO ) 
 
 Probabilities at 1 y 
(95% CI) 
Probabilities at 2 y 
(95% CI) 
Probabilities at 5 y 
(95% CI) 
Recurrence score  
0-4 8.24 (5.91–10.57) 12.6 (9.76–15.44) 20.98 (17.33–24.63)
5-6 12.07 (7.95–16.19) 22.28 (16.93–27.63) 35.57 (29.18–41.96 
7-9 25.36 (19.56–31.16) 39.61 (32.93–46.29) 47.65 (40.55–54.75)
10-16 41.79 (28.05–55.53 52.55 (38.48–66.62) 67.61 (53.67–81.55)
Progression score  
0-4 1.17 (0.15–2.19) 2.16 (0.77–3.55) 3.76 (1.9–5.62) 
5-6 3 (0.82–5.18) 4.97 (2.34–7.6) 11.69 (7.57–15.81) 
7-9 5.55 (2.73–8.37) 11.95 (7.93–15.97) 21.26 (15.85–26.67)
10-14 13.97 (6.64–21.3) 24.81 (15.6–34.02) 33.57 (23.06–44.08)
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Table 7  Weights used to calculate recurrence and progression scores (CUETO) 
Factor Recurrence score Progression score 
Gender  
Male 0 0 
Female 3 0 
Age(y)  
＜60  0 0 
60-70 1 0 
≥70  2 2 
Prior recurrence rate  
No 0 0 
Yes 4 2 
Number of tumors  
＜3 0 0 
≥3 2 1 
T Category  
Ta 0 0 
T1 0 2 
Associated Tis  
No 0 0 
Yes 2 1 
Grade  
G1 0 0 
G2 1 2 
G3 3 6 
Total score 0-16 0-14 
 
3.9 Statistics 
Differences in characteristics of patients in different risk groups were tested using chi-square, 
Fisher-exact and Mann-Whitney-Wilcoxon tests where appropriate. No imputation of missing 
data was performed. Logistic regression analyses was used to identify categorical variables 
associated with residual tumor after second TUR. The scores for risk of progression and 
recurrence were estimated by using the EORTC and CUETO models. The Kaplan-Meier 
survival analyses was used to assess recurrence and progression curves in both models. The 
recurrence-free survival (RFS) and progression-free survival (PFS) were estimated by the 
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Kaplan–Meier method, and three EAU risk groups were compared using the log–rank test. 
Univariate and multivariate Cox proportional hazards regression analyses were used to 
identify the prognostic factors for recurrence and progression. A backward stepwise 
elimination procedure was performed to identify factors associated with survival at the 0.05 
significance level. The discriminative ability of the two models was assessed using Harrell’s 
c-index, where 1.0 and 0.5 reflected perfect prediction and agreement by chance, respectively.  
A p-value of less than 0.05 was considered statistically significant for all tests. All statistical 
analyses were conducted by using IBM SPSS version. 19.0 (IBM Co., Armonk, NY, USA) 
and R 3.1.2 (R Project, www.r-project.org). 
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4  Results 
4.1. Patients Characteristics  
4.1.1 Demograpic and Clinical Data 
Between January 2003 and December 2011, 611 patients with histology-proven NMIBC were 
included in our study. Of the 611 patients, 83 (13.5%) were lost to follow-up and 525 (85.9%) 
were diagnosed firstly with primary tumor in our institution. The median follow-up was 60 
months (range: 1-143 months). According to the EAU classification of NMIBC, all patients 
were divided into the low, intermediate and high risk groups in the present study. Of the total 
patients, 197 (32%) had low, 251 (41%) intermediate and 163 (27%) high-risk, respectively 
(Figure 1).  
 
Intermediate
risk,
251, 41%
High risk,
163, 27% Low risk,197, 32%
 
Figure 1 The proportion of NMIBC according EAU classification 
 
Overall, 65 patients (10.6%) underwent radical cystectomy during follow-up, and the 
postoperative histological examination indicated heterogeneous outcomes. 4 of these patients 
were diagnosed without tumor after radical cystectomy. Another 29 patients were reported 
with pTis, Ta and T1 disease. The remaining 32 patients (49.2%) progressed to stage T2 or 
higher based on the pathological reports.  
The distribution of age is indicated in Figure 2. Median age of the patients was 71 years 
(range: 28-98 years) and the male to female ratio was 3.4:1 (471 men and 140 women). In our 
cohort, 77.1% were men with a median age of 70 years (range: 28-98 years) as opposed to 
women with 74 years (range: 29-91 years) (Figure 3).  
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Figure 2 Distribution of age in patients with NMIBC (N=611) 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Age characteristics between male and female patients 
 
In both male and female patients, the age group 61-80 years included approximately 2/3 of all 
patients, but the proportion of women older than 80 years was significantly higher than in 
men (25.0 % vs. 13.6%) (Figure 4). 
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Figure 4 Distribution of age in male patients compared with female patients 
 
In the low, intermediate and high-risk group, the male to female ratios were 3.3:1, 3.2:1, and 
3.4:1, respectively. The gender among three EAU risk groups was not statistically significant 
different (P=0.972) (Figure 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 Distribution of gender according to EAU classification 
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4.1.2 Operative Data 
According to the operative records, number of tumors, tumor size, and tumor location were 
collected and analyzed in the study.   
Of the patients, 456 (74.6%) had one, 124 (20.3%) 2 or 3 and 31 (5.1%) more than 3 tumors, 
respectively. Figure 6 shows the number of tumors among three EAU risk groups. There were 
only 8 patients with more than 3 tumors in the high-risk group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 Distribution of number of tumors according to EAU classification 
 
Overall, only 39 (6.4%) patients had a tumor with a diameter of at least 3cm. In the high risk 
group, 14.3% of the patients had a tumor diameter more than 3 cm (Figure 7). 
 
Based on the bladder anatomy, the locations of bladder tumor were divided generally into left 
wall, right wall, posterior wall, dome, trigone, neck, left ureteral orifice and right ureteral 
orifice. Overall, there were 163 (26.7%) patients with multifocal tumors and 33 patients 
(5.4%) with missing data regarding location (Table 8). Of the patients with unifocal location, 
the majority of tumors (74.4%) were located on side wall as well as posterior wall of the 
bladder (Figure 8). 
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Figure 7  Distribution of tumor size according to EAU classification 
 
 
Table 8 Distribution of tumor locations in cystoscopy 
 
Locations of bladder tumor Number of patients Percent(%) 
Left wall 118 19.3% 
Right wall 139 22.7% 
Posterior wall 52 8.6% 
Dome 18 2.9% 
Trigone 31 5.1% 
Bladder neck 28 4.6% 
Left ureteral orifice 10 1.6% 
Right ureteral orifice 19 3.1% 
Not sepcified 33 5.4% 
Multifocal  163 26.7% 
Toatl 611 100% 
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Figure 8 Distribution of location in patients with single bladder tumor 
4.1.3 Pathological Data 
Of the 611 patients, 462 (75.6%) had stage Ta, 143 (23.4%) stage T1 and 6 (1.0%) isolated 
pTis at first resection. Histological diagnosis was grade 1 in 312 (51.1%), grade 2 in 226
˄36.9%) and grade 3 in 73 (12.0%) of the patients, respectively. Of the 304 patients with 
pTaG1, 259 (85.2%) were documented with a primary tumor (Table 9). 
Table 9 The characteristic of tumor stage and grade 
 
Stage Grade 1 Grade 2 Grade 3 Total 
pTa  304(65.7%) 145(31.4%) 13(2.9%) 462 
pT1  8(5.6%) 81(56.6%) 54(37.8%) 143 
CIS  - - 6(100%) 6 
Total 312 226 73 611 
 
4.2 Treatment Strategy  
4.2.1 Second TURB  
Overall, there were 535 patients (87.6%) undergoing a second TURB after the initial resection 
while 76 did not. Of those patients who underwent second TURB the pathological results 
showed tumor in 107 (20.0%) of the cases. According to the risk classification of EAU, the 
rate of residual tumor was 13.2% in the low-risk, 19.5% in the intermediate-risk, and 29.8% 
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in the high-risk group, respectively. Of the 107 patients with residual tumor 24 were at low-, 
44 at intermediate- and 39 at high-risk, respectively (Figure 9). Thus, a significant difference 
was found in residual tumor rate among three EAU risk groups (P=0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 Distribution of second resection according to EAU classification 
 
The results showed that 16.9% of pTa BC had residual tumor at second TUR compared to 
31.1% of pT1 BC. The main features, including age, gender, prior recurrence rate, number of 
tumors, tumor size, stage and grade, were analyzed between the residual and no residual 
tumor groups. There were a significant difference in variables of age, number of tumors, stage, 
and grade (P＜0.05, respectively). In addition, the residual rate was associated with the EAU 
risk classification (Table 10). Moreover, the logistic regression results showed that number of 
tumors and tumor grade were independent variables for predicting residual tumor (Wald 
statistic P＜0.001 and P=0.002, respectively) . 
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Table 10  Patients characteristics of residual tumor group compared with no residual tumor 
group after second TURB 
Variable 
Residual tumor 
Group 
No residual 
tumor Group 
P-value 
Age (years)   0.009 
≤70 41 224  
＞70 66 204  
Gender   0.337 
Male 85 321  
Female 22 107  
Prior recurrence rate   0.900 
Primary 92 370  
Recurrence 15 58  
Number of  tumors   ＜0.001 
1 66 330  
2-3 27 84  
＞3 14 14  
Tumor size    0.681  
＜3cm 100 395  
≥3cm 7 33  
T category   0.001 
Ta 70 344  
T1 37 82  
Grade   0.002 
G1 42 247  
G2 48 139  
G3 17 42  
EAU Classification   0.001 
Low risk 24 157  
Intermediate risk 43 177  
High risk 40 94  
 
According to the 2002 TNM classification and the 1973 World Health Organization (WHO) 
system, the percentage of residual tumor was 16.9% in pTa and 31.1% in pT1 group, 
respectively. 2 pTis patients had also residual tumor at second TUR. The residual tumor rate 
based on stage and grade is shown in Table 11.  
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Table 11 Distribution of residual tumor rates at second TURB 
 
Stage Grade 1 Grade 2 Grade 3 Total 
pTa 41/281 (14.6%) 28/122(22.9%) 1/11(9.1%) 70/414(16.9%) 
pT1 1/8 (12.5%) 20/65(30.8%) 16/46(34.7%) 37/119(31.1%) 
Total 42/289(14.5%) 48/187(25.7%) 17/57(29.8%) 523 
 
Analyzing the change of histology at second TURB, of the 67 low and intermediate risk 
patients, only 6 had a higher stage at second resection. In contrast, of the high risk patients 8 
tumors were upstaged. However, of theses cases 7 had a lower staged in the second TURB 
(Figure 10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure10  Upstaging and downstaging of histology after second TURB 
 
Of the 107 patients with residual tumor at second TURB, 80 underwent a third section. Figure 
12 shows that there were still 29 patients (36.2%) with persistent tumor, including 1 with 
downstaging, 2 with upstaging and 26 at the same stage.  
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Figure 11 Distribution of risk in persistent tumor group undergoing third TURB compared with 
no residual tumor 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 Residual tumor in primary TaG1/G2 bladder tumor compared with non-primary 
TaG1/G2 bladder tumor group 
In the subgroup analyses, there were 378 (61.9%) patients with primary TaG1 (307) and TaG2 
(71) bladder cancer in our cohort. Of these patients, 199 (52.6%) were low-risk tumors and 
179 (47.4%) had intermediate-risk. Furthermore, of the 339 TaG1/G2 (89.6%) patients who 
underwent a second TURB, 58 (17.1%) had residual tumor detected by second TURB, and the 
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negative to positive ratio was 4.8:1 and 3.0:1, in primary TaG1/G2 and non-primary TaG1/G2, 
respectively (P=0.028) (Figure 12). 
 
The interval between first and second resection ranged normally from 2 weeks to 8 weeks in 
our study. Of the 535 patients who underwent a second TURB, the majority (40.3%) had this 
procedure between 36 days and 42 days after the initial TURB. The remaining groups were 
≤28 days, 29-35 days, 43-49 days, and 50-56 days in 22 (5.4%), 97 (22.3%), 94 (22.5%), and 
35 (8.4%) patients, respectively (Figure 13). Thus, the time interval in 40.9% of the patients 
treated with second TUR was more than 2-6 weeks, which is recommended in the EAU 
guidelines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13 Interval between first and second TURB (range : 2-8 weeks) 
4.2.2 Adjuvant Intravesical Treatment 
According to the EAU guidelines local adjuvant intravesical treatment was recommended to 
the NMIBC patients. Of 285 patients who were documented with intravesical treatment, 237 
underwent either one immediate instillation of doxorubicin after initial TURB or 
metaphylaxis with one or more instillation-cycles (Doxorubicin or Mitomycin-C) , and 48 
high-risk patients received BCG immunotherapy with or without maintenance scheme . 
Of these patients with doxorubicin or Mitomycin-C instillation, 139(58.6%) had recurrence 
during follow-up. Furthermore, the result indicated that high-risk patients were preferentially 
selected for adjuvant treatment. In fact, higher recurrence rate resolved in higher instillation 
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chance. Meanwhile, 20 (8.4%) advanced into MIBC during follow-up. In the group with BCG 
immunotherapy, 24(50.0%) patients had recurrence, and 6 (12.5%) patients advanced further 
to stage T2 or higher during follow-up. 
4.3 Predicting Disease Recurrence and Progression 
4.3.1 Recurrence and Progression 
Between January 2003 and December 2011, 528 patients with histology-proven NMIBC were 
included in our follow-up study. Two hundred and fifty-nine patients (49.1%) recurred during 
follow-up, and forty-six (8.7%) advanced into muscle-invasive BC. Median follow-up for 
patients who did not experience disease recurrence was 56 months and 61 months for those 
who did not experience disease progression. The overall recurrence rates of our series were 
18.6%, 33.7%, and 43.9% at the first, second, and fifth year, respectively. The overall 
progression rates were 0.9% at first, 2.6% at second, and 6.6% at the fifth year.  
Of the patients who had at least 1 recurrence during follow-up, the median time of 
recurrence-free survival (RFS) was 16 months (range: 3-123months). The average number of 
recurrences was 1.9 (range: 1-14 recurrences). The mean time of RFS was 21.6 months (range: 
3-86 months) for patients at high-risk, 27.4 months (range: 3-123months) at intermediate-risk, 
and 64.9 months (range: 3-103 months) at low-risk, respectively. The recurrence rate was 
34.1%, 56.5% and 57.1% in the low, intermediate and high risk group, respectively (Figure14; 
P＜0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14 Distribution of recurrence according to EAU risk classification 
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In the anlayses of disease progression, an invasive carcinoma of stage T2 or higher were 
found in 49 patients. The median time of progression-free survival (PFS) was 40 months 
(range: 5-123 months). Of 415 Ta patients at initial diagnosis, 23 (5.5%) developed directly 
into stage T2 or higher during follow-up, whereas 26 (6.3%) advanced from stage Ta to stage 
T1. Of the 108 T1 patients, 26 (24.1%) progressed directly into muscle-invasive stage. The 
higher stage was related to higher progression risk to MIBC (P＜0.001). 
Figure 15 shows the disease progression among three EAU risk groups. Of the patients in the 
low risk group according to the EAU classification 3 and 2 patients progressed from stage Ta 
to T1 and stage Ta to T2 or higher, respectively. Of the intermediate and high risk group 38 
(17.0%) and 32 (25.4%) progressed. The patients with higher risk had a greater probability to 
develop MIBC or to progress from lower to higher stage (P＜0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15 Distribution of progression according to EAU risk classification 
4.3.2 Prognostic Factors of RFS and PFS 
In order to predict the short-term and long-term risks of disease recurrence and progression, 
all clinical and pathological factors including age, gender, prior recurrence rate, stage, grade, 
tumor size, number of tumors, second TURB and interval between first and second resection 
were analyzed concerning RFS and PFS,.  
4.3.2.1 Prognostic Factors of RFS  
The results of univariate and multivariate Cox regression analyses for recurrence risk based 
on clinical and pathological factors are shown in Table 12. Univariate analyses revealed that 
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prior recurrence rate, T category, second TURB and second TUR pathology were significantly 
associated with RFS.  
Furthermore, prior recurrence rate and second TUR pathology were independent risk factors 
for RFS according to multivariate analyses. Compared with patients with recurrent tumors, 
the RFS rate of patients with primary bladder tumors was significantly higher (P=0.001) 
(Figure16 A). The recurrence risk associated with positive pathology at second TUR was 
significantly higher compared with those with negative pathology (P=0.010) (Figure 16 D).  
Table 12 Univariate and multivariate Cox regression analyses for RFS 
Univariate  Multivariate 
Variable 
HR 95% CI P-Value HR 95% CI P-value
Age(years):  
 ≤70  vs ＞70  1.005 0.890-1.136 0.931   NS 
Gender:  
Male vs Female 0.847 0.631-1.138 0.271   NS 
Prior recurrence rate:  
Primary vs Recurrence 1.805 1.339-2.433 <0.001 1.728 1.253-2.382 0.001 
Number of tumors:  
Single vs Multifocal 1.174 0.885-1.558 0.266   NS 
Tumor size:  
＜3cm vs ≥3cm 0.966 0.582-1.602 0.893   NS 
T category:  
Ta vs T1 1.378 1.033-1.838 0.029   NS 
Grade:  
G1, G2, G3 
G1/2 vs G3 
1.186 
0.891 
0.996-1.412
0.712-1.113
0.056 
0.309   NS 
Second TURB: 
Yes vs No  1.592 1.066-2.377 0.023   NS 
Second TUR pathology: 
Negative vs Posiitive 1.519 1.108-2.084 0.009 1.514 1.104-2.078 0.010 
Interval(days): 
≤42, ≥43 1.078 0.798-1.458 0.624   NS 
*NS: No significant. 
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                  A                                 B 
  
                  C                                 D 
Figure 16 Kaplan-Meier survival curves of recurrence free survival (RFS) in patients with 
NMIBC according to prior recurrence rate˄ A˅ˈ T stage (B), second TURB (C) and second TUR 
pathology (D) 
 
4.3.2.2 Prognostic Factors of PFS  
Regarding the analyses of prognostic factors associated with disease progression, only 
progression to stage T2 or higher was considered. The relationships between clinical 
parameters and PFS are shown in Table 13.  
Using univariate analyses, age, prior recurrence rate, tumor stage, tumor grade, second TURB 
and second TUR pathology were significantly associated with PFS.  
Multivariate analyses identified age, prior recurrence rate, tumor stage, tumor grade, and 
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second TUR pathology as independent prognostic factors associated with the risk of tumor 
progression (Table 13 and Figure 17). Compared with predicting the risk of recurrence, more 
variables were associated with predicting progression. 
Table 13  Univariate and multivariate Cox regression analyses for PFS 
 
Univariate  Multivariate 
Variable 
HR 95% CI P-Value HR 95% CI P-value
Age (years):  
 ≤70  vs ＞70  1.761 1.291-2.403 <0.001 1.575 1.085-2.288 0.017 
Gender:  
Male vs Female 1.164 0.671-2.198 0.638   NS 
Prior recurrence rate:  
Primary vs Recurrence 2.072 1.095-3.924 0.025 2.568 1.193-5.527 0.016 
Number of tumors:  
Single vs Multifocal 1.740 0.957-3.163 0.069   NS 
Tumor size:  
＜3cm vs ≥ 3cm 0.622 0.151-2.561 0.510   NS 
T category:  
Ta vs T1 4.690 2.639-8.336 <0.001 2.460 1.116-5.422 0.026 
Grade:  
G1, G2, G3 
G1/2 vs G3 
2.687 
1.609 
1.824-3.959 
1.118-2.316 
<0.001 
0.010 
1.887 
  
1.082-3.289 
  
0.025 
  
Second TURB: 
Yes vs No  
 
5.257 
 
2.733-10.112
 
<0.001   0.015 
Second TUR pathology: 
Negative vs Positive 2.599 1.304-5.177 0.007 2.381 1.187-4.775 0.015 
Interval(days): 
≤42, ≥43 0.810 0.358-1.831 0.612   NS 
*NS: No significant. 
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                  A                                 B 
 
                  C                                 D 
  
                  E                                  F 
Figure 17 Kaplan-Meier survival curves of PFS(Progression to MIBC) in patients with NMIBC 
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according to age˄A˅ˈ prior recurrence rate (B), T Stage (C), Grade (D), second TURB (E) and 
second TUR pathology (F) 
4.3.2.3 Prognostic Factors of RFS and PFS in Patients with Primary TaG1 and TaG2 
Bladder Tumor- A Subgroup Analyses 
In a subgroup analyses, 336 patients with primary TaG1 and TaG2 were analyzed to identify 
the relative predictive variables in RFS and PFS. Age, gender, number of tumors, tumor size, 
second TURB, second TUR pathology, and interval between first and second TURB were 
taken into account in the univariate analyses. In the RFS analyses, only second TUR 
pathology was significantly associated with RFS (P=0.030) (Figure 18), whereas other factors 
were not correlated to RFS. Similarly, all mentioned variables were analyzed with regard to 
PFS in the univariate analyses. Age (P=0.007) and second TURB (P<0.001) were found to be 
associated with PFS (Figure 19). 
  
Figure 18  Kaplan-Meier survival curves of RFS in patients with primary TaG1 and TaG2 
bladder tumor according to second TUR pathology  
 
4 Results 
42 
 
A                                 B 
Figure 19  Kaplan-Meier survival curves of PFS in patients with primary TaG1 and TaG2 
bladder tumor according to age˄A˅and second TURB (B) 
4.3.2.4 EAU Classification System in TaT1 Bladder Cancer 
According to the EAU guidelines, patients were divided into low, intermediate and high risk 
categories. Overall, the risk stratification was significantly associated with disease recurrence 
(P＜0.001). According to the Log Rank test, there was a statistical difference between the low 
and intermediate risk group (P＜0.001). However, no difference between the intermediate and 
the high risk group was observed (P=0.606). A significant difference was found for 
progression risk between three EAU risk groups (P＜0.001), low risk versus intermediate risk 
( P＜0.001) and intermediate risk versus high risk (P＜0.001), respectively (Figure 20).  
 
                  A                                 B 
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Figure 20 Kaplan-Meier survival curves of recurrence free survival (A) and progression free 
survival (B) according to EAU risk classification 
4.4 Dimcriminative Abilities for the EORTC and CUETO Models 
Table 14 shows the distribution of basic clinical and pathological parameters in our cohort 
compared with the similar studies of the EORTC and CUETO group. The major differences 
include: (1) the proportion of patients older than 70 years was approximately 50% and thus 
much higher than in the EORTC and CUETO studies (31%); (2) the percentage of patients 
with recurrent tumors was much lower than the EORTC study (15.2% vs 44.5%); (3) the 
proportion of patients with more than 3 tumors, tumor size more than 3cm in diameter and 
stage T1 in our cohort were 23% vs 42-50%, 7% vs 18-45%, and 21% vs 42-77% as opposed 
to the both EORTC and CUETO cohorts, respectively. 
The recurrence and progression probabilities at 1 and 5 years and the corresponding reference 
probabilities as determined by the EORTC risk tables for each risk group are listed in Table 15. 
The EORTC recurrence score was 0 in 175 patients, 1 or 4 in 273 patients and 5 to 9 in 79 
patients. There was only 1 patient with a score in the 10 to 16 range. Thus, there was no 
analyses of this highest score group.  
The actual recurrence rates in our cohort were summarized and compared with the EORTC 
recurrence prediction (Table 15). In the group of score 0, there were 25 patients (14.3%) with 
recurrence at the 1st year and 54 patients (30.9%) at 5 years. In patients with the lower 
intermediate risk (score 1-4 group), recurrence rates of 19.1% at the 1st year and of 49.4% at 
5 years were noted. In the score 5-9 group with higher intermediate risk, recurrence rates of 
25.3% at the 1st year and of 53.2% at 5 years were documented. The recurrence rates in those 
patients were overestimated at 1 and 5-year applying the EORTC scoring system (25% vs 
38%; 53% vs 62%, respectively). 
The same analyses were carried out with regard to progression. All patients were divided into 
four groups of progression risk: the score 0 group with a low risk, the score 2-6 with an 
intermediate risk, the score 7-13 group with an lower high risk, and the score 14-23 group 
with a very high risk of progression. The EORTC progression score was 0 in 248 patients, 2 to 
6 in 206 patients, 7 to 13 in 74 patients. No patients was found in the score 10 to 16 . In the 
score 0 group, there was no progression at 1 year but 9 patients had progressed (3.6%) at 5 
years. In those patients with an intermediate risk disease (Score 2-6), progression rates of 
1.4% at the 1st year and of 7.8% at 5 years were found. In the score 7-13 group with a lower 
high risk, progression rates of 2.7% at the 1st year and 17.5% at 5 years were documented. In 
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contrast to 5% progression in 1 year according the EORTC risk tables, our result had a lower 
probability (2.5%) to muscle-invasive stage. However, there was not patient with the score 
14-23 in our study. 
 
Table 14  Differences of  patient characteristics among Jena ,EORTC and CUETO studies 
Variable Jena(%) EORTC(%) CUETO(%) 
Age(years)    
≤60 96 (18.2) 33.1 31.2 
61-70 170 (32.2) 34.3 37.6 
71-80 184 (34.8) 26.6 28.3 
＞80 78 (14.8) 4.5 2.9 
Gender    
Male 403 (76.3) 78.7 - 
Female 125 (23.7) 19.8 - 
Prior recurrence rate    
Primary 448 (84.8) 54.1 66.7 
≤1 recurrence/y 19.5 
＞1 recurrence/y 80 (15.2) 24.8 
33.3 
Number of tumors    
1 407 (77.1) 56.4 49.2 
2-3 96 (18.2) 32.2 26.9 
＞3 25 (4.7) 9.8 23.9 
Tumor size(cm)    
＜3 493 (93.4) 80.4 54.2 
≥3 35 (6.6) 17.9 45.8 
T category    
Ta 415 (78.6) 55.9 19.4 
T1 108 (20.5) 42.7 77.2 
Grade    
G1 288 (54.5) 43.2 15.2 
G2 189 (35.8) 43.9 57.9 
G3 47 (8.9) 10.4 23.5 
Concomitant CIS    
No 516˄97.7˅ 94.0 89.7 
Yes 12˄2.3˅ 4.4 10.3 
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Table 15  Probability of recurrence and progression at 1 and 5 years based on the weighted 
variables according to the EORTC score 
Probabilities at 1 y (%) Probabilities at 5 y (%) 
Variable Patients(n) 
Jena(%) EORTC(%) Jena(%) EORTC(%) 
Recurrence score      
0 175 14.3 15 (10-19) 30.9 31 (24-37) 
1-4 273 19.1 24 (21-26) 49.4 46 (42-49) 
5-9 79 25.3 38 (35-41) 53.2 62 (58-65) 
10-17 1 - 61 (55-67) - 78 (73-84) 
Progression score      
0 248 0 0.2 (0-0.7) 3.6 0.8 (0-1.7) 
2-6 206 1.4 1 (0.4-1.6) 7.8 6 (5-8) 
7-13 74 2.7 5 (4-7) 17.5 17 (14-20) 
14-23 0 - 17 (10-24) - 45 (35-55) 
 
Kaplan-Meier survival curves for the 3 risk groups were plotted for recurrence and 
progression in Figure 21 and 22, and a statistically significant difference were found among 
different score groups (Log-rank P＜0.001). To assess discriminative abilities of the EORTC 
models, concordance index of the EORTC models was 0.567 for recurrence and 0.675 for 
progression, respectively.  
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*O = Observed number of recurrence; R= Number of cumulative recurrence 
 
Figure 21  Kaplan-Meier survival curves of risk of recurrence using EORTC recurrence score 
 
 Total 12m 24m 36m 48m 60m 72m 84m Recurrence 
O 175 145 114 98 80 58 33 24 EORTC 0 
R 62 25 43 51 53 54 56 58   
O 273 210 153 129 89 71 43 28 EORTC 1-4 
R 150 52 99 116 133 135 140 144  
O 79 57 38 29 23 16 12 12 EORTC 5-9 
R 46 20 35 39 40 42 44 44  
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*O = Observed number of progression; P= Number of cumulative progression 
Figure 22  Kaplan-Meier survival curves of risk of progression using EORTC progression score 
 
Using the same method, the recurrence and progression probabilities at 1, 2 and 5 years and 
the corresponding reference probabilities based on the CUETO risk tables for each risk group 
are shown in Table 16.  
The CUETO recurrence score was 0 to 4 in 378 patients, 5 or 6 in 103 patients, 7 to 9 in 41 
patients, and 10 to 16 in 3 patients. We compared our actual recurrence rates with the CUETO 
predictions among the four groups. There was not a statistical value in the forth group because 
of only 3 patients enrolled in our cohort.  
In contrast to the corresponding reference probabilities in the CUETO risk table the 
recurrence rates in our series were generally higher in the 4 groups regardless of the time 
point (1,2 and 5 years; Table 16).  
 Total 12m 24m 36m 48m 60m 72m 84m Progression 
O 248 240 217 198 160 124 83 59 EORTC 0 
P 11 0 2 4 6 9 10 10   
O 206 190 168 148 114 93 62 43 EORTC 2-6 
P 22 3 6 11 15 16 18 20  
O 74 70 60 54 40 27 18 15 EORTC 7-13 
P 16 2 6 7 10 13 13 14  
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For the progression risks, patients were divided into four groups based on the progression 
score: the first group with score 0-4, the second group with score 5-6 , the third group with 
score 7-9, and the forth group with score 10-14. The CUETO progression score was 0 to 4 in 
412 patients, 5 or 6 in 62 patients, 7 to 9 in 29 patients, and 10 to 14 in 25 patients. In the first 
group, there were a progression incidence of 0% at the 1st year , 4 patients (0.9%) at 2 years 
and 16 patients (3.9%) at 5 years. In the second group, progression rates of 1.6% at the 1st 
year, 4.3% at 2 years and of 11.3 % at 5 years were reported. In the third group, progression 
rates of 6.9% at the 1st year, 13.8% at 2 years and 31.0% at 5 years were documented. The 
progression rates in the forth group were 8.0% at the 1st year, 12.0% at 2 years, and 24.0% at 
5 years, respectively. 
Figure 23 and Figure 24 present the Kaplan-Meier survival curves in the four groups for 
recurrence and progression. The curves reveal a significant difference among the 4 categories 
based on the CUETO score (Log-rank P＜0.001). To assess discriminative abilities of the 
CUETO models, concordance index of the CUETO models was 0.526 for recurrence and 
0.705 for progression, respectively.  
 
Table 16  Probability of recurrence and progression at 1, 2, and 5 years based on the weighted 
variables according to the CUETO score 
Probabilities at 1 y (%) Probabilities at 2 y (%) Probabilities at 5 y (%) 
Variable 
Patients 
(n) Jena(%) CUETO(%) Jena(%) CUETO(%) Jena(%) CUETO(%)
Recurrence score        
0-4 378 17.2 8 (6-11) 31.7 13 (10–15) 41.9 21 (17-25) 
5-6 103 18.4 12 (8-16) 33.0 22 (17–28) 41.7 36 (29-42) 
7-9 41 31.7 25 (20-31) 48.7 40 (33–46) 65.8 48 (41-55) 
10-16 3 33.3 42 (28-56) 66.7 53 (38–67) 66.7 68 (54-82) 
Progression score        
0-4 412 0 1.2 (0.2-2.2) 0.9 2.2 (0.8–3.5) 3.9 3.8 (1.9-5.6) 
5-6 62 1.6 3 (0.8-5.2) 4.8 5 (2.3–7.6) 11.3 12 (7.6-16) 
7-9 29 6.9 5.6 (2.7-8.4) 13.8 12 (8–16) 31.0 21 (16-27) 
10-14 25 8.0 14 (6.6-21) 12.0 25(16–34) 24.0 34 (23-44) 
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*O = Observed number of recurrence; R= Number of cumulative recurrence 
 
Figure 23  Kaplan-Meier survival curves of risk of recurrence using CUETO recurrence score 
 
 
 
 
 
 
 
 
 Total 12m 24m 36m 48m 60m 72m 84m Recurrence 
O 381 302 226 188 141 111 76 46 CUETO 0-4 
R 178 65 121 142 156 160 167 172   
O 103 80 60 53 40 29 18 14 CUETO 5-6 
R 50 19 34 40 42 43 45 46  
O 41 28 18 14 7 4 3 3 CUETO 7-9 
R 29 13 21 23 27 27 27 27  
O 3 2 1 1 1 1 1 1 CUETO 10-16
R 2 1 2 0 0 0 0 0  
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*O = Observed number of progressions; P= Number of cumulative progression 
 
Figure 24 Kaplan-Meier survival curves of risk of progression  using CUETO progression score 
 
 
 
 
 
 Total 12m 24m 36m 48m 60m 72m 84m Progression 
O 412 394 352 319 254 200 134 95 CUETO 0-4 
P 22 0 4 10 13 16 17 18   
O 62 58 50 41 34 27 19 15 CUETO 5-6 
P 10 1 3 4 6 7 8 9  
O 29 26 22 20 14 10 6 3 CUETO 7-9 
P 11 2 4 5 8 9 10 11  
O 25 22 21 20 12 7 4 4 CUETO 10-14
P 6 2 3 3 4 6 6 6  
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5  Discussion 
5.1 Clinical and Pathological Characteristics 
To identify the important variables associated with disease recurrence and progression, a 
retrospective NMIBC study was performed in our institution. Overall, 611 patients with 
NMIBC were identified between January 1, 2003 and December 31, 2011, including 471 men 
and 140 women which equals a male to female ratio of 3.4:1. The median age of 74 years in 
women was greater than 70 years in men. Thus, our cohort resembles a typical bladder cancer 
population. Of the patients 528 were followed up excluding those undergoing cystectomy 
directly and with incomplete data after initial TUR etc. The median follow-up duration was 60 
months (range: 1-143 months), and 448 (84.8%) were diagnosed with primary BC disease.  
In general, clinical characteristics of NMIBC patients vary in different regions and countries, 
which have been reported in several investigations (Rianne et al.2014, Kohjimoto et al. 2014). 
Schulze and colleagues assessed 251 german NMIBC patients with a mean follow-up of 69 
months in 2007, which showed 2.6:1 of male to female ratio, and 85% patients with primary 
BC (Schulze et al. 2007). Other studies also showed slight differences of clinical 
characteristics based on local demographic data (Lazica et al.2014, Grimm et al. 2003). 
According to the EORTC and CUETO scoring systems and risk tables (Sylvester et al. 2006, 
Fernandez-Gomez et al. 2009), all clinical and pathological data were collected to predict 
disease recurrence and progression, including gender, age, prior recurrence rate, number of 
tumors, tumor size, tumor stage, tumor grade, and presence of CIS. However, the risk scoring 
of the EORTC is exclusively based on studies, in which no second TUR and no BCG 
maintenance therapy was applied.  
Meanwhile, some studies have demonstrated that second TUR plays an important role to 
determine the therapeutic strategy and reduce disease recurrence rates (Dobruch et al. 2014, 
Kim et al.2012). Therefore, location of the tumors at initial TUR, second TUR, and second 
TUR pathology are further included in the present study.  
Compared to the patient characteristics of the EORTC and CUETO studies, there is some 
variation in our cohort. Firstly, the proportion of elderly patients more than 70 years was 
higher (50% in our study vs. 31% according to EORTC and CUETO studies) in our institution. 
Secondly, the percentage of recurrent tumors was lower (15% vs. 33-45%). Thirdly, the 
proportion of stage T1 tumors was significantly reduced (21% vs. 42-77%). Thus, the number 
of high-risk patients was relatively smaller than in both large scale studies. 
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In the past, the majority of studies focused on NMIBC using the classification based on stage 
and grade only (Soloway et al.2006, Lazica et al. 2014, Takaoka et al.2013). In the present 
study, NMIBC patients were stratified into low, intermediate and high risk category according 
to the EAU guidelines subsequently facilitating to define an accurate therapeutic scheme. Of 
these patients 197 (32%) had low-risk, 251(42%) intermediate-risk and 163 (26%) high-risk, 
respectively.  
With respect to the distribution of tumor locations, there were 26.7% patients with multifocal 
and 42% single tumors of the side walls. This result was quite similar with previous findings 
from another german hospital reporting multiple tumors in 33% patients and single tumor of 
the side walls in 47% patients (Schulze et al. 2007). 
5.2 Second TURB 
A second TURB should be performed generally within 2-6 weeks if incomplete resection 
tumors, no muscle in original specimen for high grade tumors, multifocal tumors and any T1 
in NMIBC patients (Babjuk et al. 2011), which have been recommended by EAU guidelines. 
Moreover, the residual tumor rate detected by a second TUR varies between 27% and 78% 
(Babjuk et al. 2011). 
Some authors focused only on second TURB in stage Ta or T1 high-grade NMIBC. A 
randomized trial performed by Divirik and associates demonstrated that second TURB after 
complete first TURB could significantly decrease the recurrence and progression rates in 
patients with primary diagnosed T1 BC (Divrik et al. 2010). Likewise, Sfakianos et al. 
suggested that second TURB should be performed before initial BCG therapy for NMIBC, 
which was drawn from the analyses of 1,021 patients (Sfakianos et al.2014).  
Generally, second resection is not recommended in low-grade bladder tumors, because it does 
not alter treatment strategy (Herr 2011). However, a 5-year observational study performed by 
Grimm and coworkers indicated that recurrence-free rate was 63% in patients undergoing 
second TUR compared with 40% of patients after TUR alone (Grimm et al. 2003). 
Furthermore, there were residual tumors in 27% of pTa and 53% of pT1 patients. In our 
present study, 16.9% of pTa patients had residual tumor after second TUR, but only 31.1% in 
pT1 patients. However, patients in the study by Grimm et al. were treated between 1993 and 
1995 while the present cohort underwent TUR after 2003. Thus, improvements in 
camera-systems used during TUR might have contributed to the lower tumor rate detected by 
second TURB. 
According to the EAU classification the rate of residual tumor after second TUR was 13.2% 
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in low-risk , 19.5% in intermediate-risk and 29.6% in high-risk patients, respectively. Thus, 
the residual tumor rate was significantly associated with EAU risk categories. In order to 
better understand the features of primary TaG1 and TaG2 tumors, we performed a subgroup 
analyses and compared primary TaG1/G2 cases with the remaining NMIBC patients. The 
results indicated that the residual tumor rate was significantly reduced in primary TaG1/G2 
group. 
We analyzed further downstaging and upstaging after second TUR compared with first 
pathological diagnosis. Of the 67 patients with low and intermediate risk at primary TUR, 
6(8.9%) had a higher stage at second resection. In the high-risk cases, 8(20%) were found 
upstaged and 7 (17.5%) had however a lower stage after second TUR. A prospective study 
published by Ali et al also showed that 20% of pTa patients developed into pT1 at second 
TUR, and 26.2% of pT1 cases progressed into muscle-invasive disease. In that study 14.8% of 
the pT1 patients were downstaged to stage pTa (Ali et al. 2010). The authors concluded that 
second TUR was recommended for T1, high grade, nodular tumors with a diameter of at least 
3cm tumors. However, considering the present study the risk of understaged NMIBC is 
significant and, considering its impact on subsequent treatment modalities in the upstaged 
patients, should be carefully considered based on risk category. 
Of the 107 patients with residual tumor detected by second TUR, 80 (74.8%) even underwent 
a third TUR. The results showed that of the patients 36.2% still had persistent tumor including 
1 with lower, 2 with higher and 26 with the same stage, respectively. The rate of persistent 
tumor was significantly correlated to the EAU risk groups (P＜0.05). Those patients might 
need close observation or to undergo an aggressive therapeutic strategy. Thus, third TURB 
might further help clinicians to distinguish between immediate radical cystectomy and 
intravesical therapy, as the majority of patients with residual T1 disease at second TUR 
developed probably into muscle-invasive disease.  
Süer and colleagues showed that a prolonged interval between first and second TURBT was 
an independent predictor for residual tumor detection in high-grade T1 cases (Süer et al. 
2013). Furthermore, Baltaci et al. reported that time interval between first and second TUR 
should to be less than 42 days in patients with high-risk NMIBC treated with BCG 
maintenance instillation, in order to obtain lower recurrence and progression rates (Baltaci et 
al. 2014). Therefore, we considered the time interval as a potential prognostic factor for 
disease recurrence and progression in our study. However, we could not confirm these 
observations in our high-risk cases. To our knowledge, most authors recommend the second 
TUR at 2-6 weeks after initial TUR (Babjuk et al. 2011). However, our results indicate that 
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this is difficult in clinical practice as only 68 % of our patients stayed within the 42 days time 
frame (69%) while 31% of our patients underwent second TUR between days 43-56.  
5.3 Recurrence and Progression in Follow up 
Of the NMIBC patients, recurrence is the main problem for stage pTa patients, whereas 
progression is the main potential life-threatening aspect in pT1 and CIS cases (van Rhijn et al. 
2009). Recurrence and progression was reported in 49.1% and 8.7% of our cases, respectively. 
Similarly, Choi et al. reported that 33.0% patients had recurrence within a mean follow-up of 
19.0 months, and 9.0% cases advanced into MIBC with 33.6 months (Choi et al. 2014). In 
addition, Linton and coauthors also published their finding in a large sample with primary 
pTaG1 bladder cancer. The author’s observed that 28.5% of the patients recurred and 4.5% 
progressed after a median period at 13.5 months and 35.7 months, respectively (Linton et al. 
2013). Based on the similar median follow-up (58-61 months vs 60 months), the greater rate 
of disease recurrence and progression in our study could be explained by the higher 
proportion of high-risk patients. However, the median RFS and PFS are comparable 
(16-19moths vs 13.5 moths; 33.6-40 moths vs 35.7months; respectively).  
With respect to recurrence, the overall recurrence rates were 18.6% and 43.9% at the first and 
fifth year. Likewise, a retrospective study conducted by Kikuchi et al based on the Japanese 
National Bladder Cancer Registry, indicated that the 1-year, 2-year, and 5-year overall 
recurrence rates were 33.0%, 38.7%, and 47.2%, respectively (Kikuchi et al. 2009). The lower 
recurrence rate in the short term in our cohort may be due to second TUR or the consistent use 
of early instillation therapy. Our results showed that the recurrence rate was significantly 
associated with the risk category of NMIBC (P＜0.001). In this setting, the mean time of RFS 
were 64.9 months, 27.4 months and 21.6 months in the low, intermediate and high risk group, 
respectively. Therefore, high risk patients should undergo close follow up within the 24 
months after initial diagnosis. 
Currently, the IBCG defines progression of NMIBC as an increase in the T stage not only as 
development of T2 or greater, but also as an increase in the T stage from CIS or Ta to T1 
(Lamm et al. 2014). In our institution the results indicated that 6.3% patients were found with 
progression from stage Ta to T1 and 5.5% pTa patients developed directly into 
muscle-invasive disease. However, the rate of progression in pT1 stage was 24.1%. In the 
subgroup analyses among different risk groups, the patients with higher risk had a greater 
probability to develop into MIBC or from pTa to pT1 (P＜0.001). Thus, a close follow up to 
detect progression early should mainly focus on stage T1 patients. 
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5.4 Prognostic Factors in Disease Recurrence and Progression 
Sylvester and colleagues proposed that the EORTC scoring system was applied to calculate an 
individual probability of recurrence and progression (Sylvester et al. 2006). Consequently, 
this method was recommended by the EAU guidelines for NMIBC. The important prognostic 
variables are prior recurrence rate, multiplicity, tumor size, tumor stage, tumor grade and 
concomitant CIS. Several investigators have reported also that second TUR played an 
important role to decrease the risk of recurrence and progression (Herr HW and Donat SM 
2006, Divrik et al. 2010). Therefore, second TUR and second TUR pathology were also 
considered as potential prognostic factors in our study. Furthermore, the time interval between 
first and second TUR was analyzed in recurrence and progression models according to the 
study of Baltaci and coworkers (Baltaci et al.2014). 
As discussed above, univariate Cox proportional hazards regression analyses revealed prior 
recurrence rate, T category, second TURB and second TUR pathology were significant 
predictors for tumor recurrence. Compared to other studies (Xu et al.2013, Sylvester et al. 
2006, Kikuchi et al. 2009), we found that number of tumors, tumor size and tumor grade were 
not associated with tumor recurrence in our cohort. This difference may be attributed to a 
possible bias in the low proportion of at least 3cm tumors and the number of tumors (more 
than 3). Of note, our patients were not enrolled in a clinical trial and documentation of tumor 
diameter and number of tumors relies on retrospective chart review. Only prior recurrence rate 
and second TUR pathology were independent risk factors for disease recurrence in 
multivariate analyses.  
With regard to progression, age, prior recurrence rate, T category, tumor grade, second TURB 
and second TUR pathology were identified as significant predictors for tumor progression. In 
the subsequent multivariate analyses, age, prior recurrence rate, tumor stage, tumor grade and 
second TUR pathology were found as independent risk factors for tumor progression. These 
results indicate that most variables were significant associated with tumor progression. The 
Kaplan–Meier curve showed the significant differences among three EAU risk groups (P 
<0.05). Nevertheless, time interval between first and second TUR was not related to risk of 
recurrence and progression which may, however, play an important role in stage pT1 or 
high-risk patients (Baltaci et al.2014).  
In the subgroup analyses with primary TaG1/G2 bladder tumors, the results indicate that only 
second TUR pathology is associated significantly with RFS, whereas age and second TUR are 
predictors in PFS. In a 10-year study of TaG1 NMIBC, Bosset and colleagues found that 
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tumor size and number of lesions were prognostic factors for disease recurrence (Bosset et al. 
2014). Moreover, Rieken et al. retrospectively analyzed 1447 patients with TaG1 BC and 
demonstrated that advancing age, tumor >3cm, multiple tumors and recurrent tumors were 
associated with increased recurrence risk. In the same study, advanced age and multiple 
tumors were independent predictors of disease progression (Rieken et al. 2014). Linton et al 
reported that low-grade dysplasia at initial resection and tumor weight were related to disease 
specific mortality (Linton et al. 2013). In contrast to these other investigations, out cohort 
contains a higher proportion of low and intermediate risk patients (Olivier et al. 2015, Linton 
et al. 2013, Rieken et al. 2014). 
5.5 EAU Classification System in TaT1 Bladder Cancer 
The EAU panel recommends urologists to stratify patients with three EAU risk categories 
based on the clinical prognostic factors and EORTC risk tables, in order to facilitate 
subsequent treatment selection. We found that the EAU risk stratification was significantly 
associated with disease progression (P＜0.001). However, it is difficult to distinguish 
recurrence risk between intermediate and high risk. In fact, the definition and management for 
intermediate risk NMIBC varies between EAU, AUA, and ICUD recommendations (Konety 
et al. 2012, Hall et al. 2007, Babjuk et al. 2013). Therefore, the IBCG recently recommended 
that multiple and at least 3 cm in size tumors, recurrence within 1 year and frequency (more 
than 1 per year) of recurrences as well as previous treatment are prediction factors to facilitate 
clinical decisions in intermediate risk NMIBC. The number of these factors was stratified into 
different therapeutic scheme (Kamat et al. 2014). The risk category should be calculated again 
at each tumor recurrence.  
5.6 Discriminative Abilities of the EORTC and CUETO Models 
Numerous studies were reported to identify prognostic factors for recurrence and progression 
of NMIBC (Sylvester et al. 2006, Fernandez-Gomez et al. 2009). Generally, the important 
prognostic factors are clinical and pathological variables, including the number of tumors, 
tumor size, prior recurrence rate, tumor stage, tumor grade, and the presence of CIS. Up to 
now, the EORTC and CUETO scoring system and risk tables are considered the most reliable 
systems.  
In 2006, Sylvester et al. developed the EORTC scoring system, which was derived from the 
data obtained from studies between 1979 and 1989 comprising 2596 NMIBC patients enrolled 
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in seven EORTC-trials. According to the mentioned six clinicopathologic variables, weighting 
scores for each factor differed depending on the severity of the specific parameter and the 
total score from all factors predicts the probability of recurrence and progression at 1-year and 
5-years. The main limitation of the EORTC model is that just 171 patients (6.6%) were treated 
with BCG instillation therapy and none of the patients received a maintenance schedule. 
Furthermore, second TUR was not part of the treatment strategy in these trials. 
To overcome this deficiency (only 6.6% with BCG therapy), a new scoring system was 
described by the CUETO group (Fernandez-Gomez et al. 2009). They reviewed data from 
four CUETO trials involving a total of 1062 patients with BCG therapy treated between 1990 
and 1999. This scoring model includes seven clinicopathologic factors, adding both age and 
gender compared to the EORTC model. In the same way, the probability of 1-year, 2-year and 
5-year recurrence and progression rates were calculated from sum scores of each factor. Their 
results demonstrated the overestimated risks of recurrence and progression in NMIBC 
patients with BCG therapy using the EORTC model. 
In order to evaluate the applicable ability of EORTC and CUETO in different countries, 
several external validation studies (Table 17) have been performed with controversial results 
(Kohjimoto et al. 2014). Although the majority of authors recommend the EORTC or CUETO 
scoring systems to manage NMIBC patients, the largest cohort study (4689 patients) 
conducted by Xylinas et al. demonstrated that both EORTC and CUETO scoring systems had 
a poor discrimination for recurrence and progression in NMIBC patients. The main finding 
was overestimated risk of disease recurrence and progression in high-risk patients, especially 
in BCG-treated patients (Xylinas et al. 2013). Therefore, EORTC and CUETO models may 
not apply to NMIBC patients treated nowadays e.g. if patients undergo routine re-resection 
and BCG maintenance therapy. In order to analyze the discriminative abilities, we calculated 
the 1- and 5-year risk of disease recurrence and progression in our cohort and compared it 
with EORTC and CUETO risk tables.  
Overall, our cohort is similar to that of the EORTC but not to that of the CUETO cohort. In 
conclusions, 79 patients with EORTC recurrence score 5-9 were overestimated at 1 and 5 
years (25% vs 38%; 53% vs 62%, repectively) and the patients with EORTC progression 
score 7-13 also exhibited a lower progression rate at 1 year (2.3% vs 5%). Thus, our results 
are similar to the conclusions of Xylinas (Xylinas et al.2013). On the other hand, our 
recurrence rates ( Table 16) showed an overestimated probabilty in all patients at the same 
time point (1,2 and 5 years) compared with the expected probabilities according to the 
CUETO risk tables. This poor discriminative ability of the CUETO recurrence risk table is not 
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surprising, considering that only 8.4% of our patients were treated with BCG therapy. 
However, the CUETO progression risk table results in a good prediction in our cohort 
regardless of the time point considered (c-index: 0.702).  
Table 17 External validation studies for the EORTC and CUETO models 
Author Country Period No. patients BCG% EORTC CUETO 
Altieri UK 2002-2011 259 23% ˇ NA 
Pillal UK 1983-1985 109 0% ˇ NA 
Hernandez Spain 1998-2008 417 8.2% ˇ NA 
Ajili Tunisia 2002-2011 112 NA ˇ NA 
Ding China 2000-2009 301 0% ˇ NA 
Seo Korea 1993-2007 251 100% ˇ NA 
Fernandez-Gomez Spain 1990-1999 1062 100% ˉ NA 
Borkowska Poland 2006-2009 91 NA ˉ NA 
Rosevear USA 1999-2001 718 100% NA ˇ 
Lammers Netherland 1987-2010 728 0% ˇ ˉ 
Xu China 2003-2010 363 0% ˇˇ ˇ 
Choi Korea 1985-2011 531 NA ˇ ˇˇ 
Kohjimoto Japan 1985-2007 366 100% ˉ ˇ 
Xylinas International 2000-2007 4689 11% ˉ ˉ 
Vedder International 1979-2012 1892 23.7% Progression Progression
Our present study Germany 2003-2011 528 8.9% Progression Progression
*:ˇ:Recommendation; ˉ:No recommendation; NA : Not Applicable. 
 
Those conclusions could be reflected through the Harrell’s concordance index. Our results are 
similar with the findings of Vedder et al (0.57 vs. 0.55 in EORTC recurrence prediction, 0.68 
vs. 0.72 in EORTC progression prediction; 0.53 vs. 0.61 in CUETO recurrence prediction, 
0.71 vs. 0.82 in CUETO progression prediction) (Vedder et al. 2014). In contrast to Xylinas’ 
conclusions, our C-indexes in recurrence prediction are 0.57 vs. 0.60 compared to EORTC 
and 0.53 vs. 0.52 compared to CUETO. Regarding disease progression C-indexes of disease 
progression are 0.68 vs. 0.66 compared to EORTC and 0.71 vs. 0.62 copmpared to CUETO 
(Xylinas et al.2013). However, other investigators have shown a higher C-index in recurrence 
(range: 0.62-0.75) and a comparable progression C-index (range: 0.65-0.77) regardless of the 
used models (Kohjimoto et al. 2014, Pillai et al.2011, Xu et al.2013) . 
In contrast to the recurrence models, the progression models of both, EORTC and CUETO, 
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appeared to be more applicable to our cohort. Furthermore, the CUETO models overestimate 
generally recurrence probabilities in our institution. Because age is an independent predictor 
in disease progression, EORTC plus the variable age maybe have a better utility for predicting 
disease recurrence and progression. 
5.7 Limitations  
There are some limitations in the present study. Given the retrospective nature of this analyses 
and long term follow-up period, not all patients were treated subsequently by the standard 
regimen or the same clinician, which might influence the treatment effect. We could not 
assess thoroughly intravesical chemotherapy or dosage and discontinuation of BCG 
instillation due to incomplete medical records. On the other hand, the quality of TUR between 
WLC and PDD period and the old classification of stage and grade might influence our results. 
Another limitation is the size of the sample, especially in the high-risk category in which the 
number of patients is relatively smaller than in other investigations. 
Even with these limitations, our results indicate the true characteristics of NMIBC patients as 
far as possible based on our cohort, which may facilitate better therapeutic strategy in our 
institution.  
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6  Conclusion 
Optimal management of NMIBC requires accurate and individual prediction of the risk for 
recurrence and progression. To date, clinical and pathological variables still are the optimized 
prognostic factors to facilitate clinicians to choose optimal therapeutic modalities. In the 
setting, age, gender, prior recurrence rate, tumor size, number of tumors, tumor stage, tumor 
grade, second TURB, second TUR pathology, and interval between first and second TUR 
were analyzed to distinguish independent prognostic factors in our cohort. The main 
conclusions are: 
In our institution, EAU risk stratification is a good tool to define the therapeutic strategy in 
patients with NMIBC. 
In subgroup analyses of primary pTaG1/G2 patients, second TUR is associated with a reduced 
risk of disease recurrence. However, advanced age and residual tumor after second TUR 
increase the progression risk in this subgroup 
In terms of the univariate analyses, prior recurrence rate, any T1, second TUR and positive 
pathology after second TUR are related to increased risk of disease recurrence, whereas age, 
prior recurrence rate, T1, high grade, second TUR, and positive pathology after second TUR 
are also significantly associated with increased risk of disease progression. 
In terms of the multivariate analyses, prior recurrence rate and second TUR pathology are the 
independent predictors in disease recurrence. Likewise, age, prior recurrence rate, tumor stage, 
tumor grade, and second TUR pathology are the prognostic factors in disease progression.  
In view of the statistical results obtained, we suggest that EORTC and CUETO progression 
risk tables are included into our clinical practice to estimate individual progression risk in 
patients suffering from NMIBC. 
In contrast to the EORTC recurrence risk table, the CUETO recurrence risk table 
underestimates completely the risk of disease recurrence in our cohort. On the other hand, 
EORTC recurrence risk table overestimates the risk in patients with higher intermediate-risk 
(recurrence score: 5-9). 
In conclusion, we propose that second TUR is of paramount importance and should be applied 
to all NMIBC patients, CUETO progression risk table is the best choice in our NMIBC 
population. Our therapeutic strategy is appropriate in the management of NMIBC patients, 
especially in high-risk patients resulting in a relatively low recurrence risk. 
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